Approved antiviral drugs over the past 50 years
E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …
categorized into 13 functional groups have been formally approved for the treatment of the …
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
G Li, E De Clercq - Antiviral research, 2017 - Elsevier
One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …
High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis
E Gane, F Poordad, S Wang, A Asatryan, PY Kwo… - Gastroenterology, 2016 - Elsevier
Background & Aims The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530
(NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment …
(NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment …
HCV virology and diagnosis
S Roger, A Ducancelle, H Le Guillou-Guillemette… - Clinics and research in …, 2021 - Elsevier
Hepatitis C virus (HCV) infection is a major cause of severe liver disease including chronic
hepatitis, cirrhosis and hepatocellular carcinoma. The HCV burden in public health is …
hepatitis, cirrhosis and hepatocellular carcinoma. The HCV burden in public health is …
VIRULIGN: fast codon-correct alignment and annotation of viral genomes
Virus sequence data are an essential resource for reconstructing spatiotemporal dynamics
of viral spread as well as to inform treatment and prevention strategies. However, the …
of viral spread as well as to inform treatment and prevention strategies. However, the …
Current antiviral drugs and their analysis in biological materials–Part II: Antivirals against hepatitis and HIV viruses
L Nováková, J Pavlík, L Chrenková, O Martinec… - … of pharmaceutical and …, 2018 - Elsevier
This review is a Part II of the series aiming to provide comprehensive overview of currently
used antiviral drugs and to show modern approaches to their analysis. While in the Part I …
used antiviral drugs and to show modern approaches to their analysis. While in the Part I …
Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis
New SARS-CoV-2 mutants have been continuously indentified with enhanced transmission
ever since its outbreak in early 2020. As an RNA virus, SARS-CoV-2 has a high mutation …
ever since its outbreak in early 2020. As an RNA virus, SARS-CoV-2 has a high mutation …
[HTML][HTML] In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture
B Torres-Vázquez, AM de Lucas… - Journal of Molecular …, 2022 - Elsevier
Hepatitis C virus (HCV) core is a highly conserved and multifunctional protein that forms the
viral capsid, making it an attractive target for HCV detection and inhibition. Aptamers are in …
viral capsid, making it an attractive target for HCV detection and inhibition. Aptamers are in …
Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time
L Cuypers, F Ceccherini‐Silberstein… - Reviews in Medical …, 2016 - Wiley Online Library
The introduction of highly potent direct‐acting antivirals (DAAs) has revolutionized hepatitis
C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the …
C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the …
Danoprevir for the treatment of hepatitis C virus infection: design, development, and place in therapy
M Miao, X **g, E De Clercq, G Li - Drug Design, Development and …, 2020 - Taylor & Francis
Abstract On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …